286 related articles for article (PubMed ID: 33093598)
1. Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism.
Senek M; Nyholm D; Nielsen EI
Sci Rep; 2020 Oct; 10(1):18057. PubMed ID: 33093598
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets.
Othman AA; Dutta S
Br J Clin Pharmacol; 2014 Jul; 78(1):94-105. PubMed ID: 24433449
[TBL] [Abstract][Full Text] [Related]
3. Levodopa-Entacapone-Carbidopa Intestinal Gel Treatment in Advanced Parkinson's Disease: A Single-Center Study of 30 Patients.
Viljaharju V; Mertsalmi T; Pauls KAM; Koivu M; Eerola-Rautio J; Udd M; Pekkonen E
Mov Disord Clin Pract; 2024 Feb; 11(2):159-165. PubMed ID: 38386490
[TBL] [Abstract][Full Text] [Related]
4. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.
Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M
Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940
[TBL] [Abstract][Full Text] [Related]
5. Levodopa-Carbidopa-Entacapone Intestinal Gel in Advanced Parkinson Disease: A Multicenter Real-Life Experience.
Szász JA; Dulamea AO; Constantin VA; Mureşanu DF; Dumbravă LP; Tiu C; Jianu DC; Simu M; Ene A; Axelerad A; Falup-Pecurariu C; Lungu M; Danci AG; Sabau M; Strilciuc Ş; Popescu BO
Am J Ther; 2024 May-Jun 01; 31(3):e209-e218. PubMed ID: 38460175
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.
Nyholm D; Odin P; Johansson A; Chatamra K; Locke C; Dutta S; Othman AA
AAPS J; 2013 Apr; 15(2):316-23. PubMed ID: 23229334
[TBL] [Abstract][Full Text] [Related]
7. Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa.
Othman AA; Rosebraugh M; Chatamra K; Locke C; Dutta S
J Parkinsons Dis; 2017; 7(2):275-278. PubMed ID: 28211816
[TBL] [Abstract][Full Text] [Related]
8. Optimization of oral entacapone administration in patients undergoing levodopa-carbidopa intestinal gel treatment.
Miyaue N; Ito Y; Yamanishi Y; Tada S; Ando R; Yabe H; Nagai M
J Neurol Sci; 2024 Feb; 457():122901. PubMed ID: 38280299
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition.
Rouru J; Gordin A; Huupponen R; Huhtala S; Savontaus E; Korpela K; Reinikainen K; Scheinin M
Eur J Clin Pharmacol; 1999 Aug; 55(6):461-7. PubMed ID: 10492060
[TBL] [Abstract][Full Text] [Related]
10. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.
Corvol JC; Bonnet C; Charbonnier-Beaupel F; Bonnet AM; Fiévet MH; Bellanger A; Roze E; Meliksetyan G; Ben Djebara M; Hartmann A; Lacomblez L; Vrignaud C; Zahr N; Agid Y; Costentin J; Hulot JS; Vidailhet M
Ann Neurol; 2011 Jan; 69(1):111-8. PubMed ID: 21280081
[TBL] [Abstract][Full Text] [Related]
11. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.
Piccini P; Brooks DJ; Korpela K; Pavese N; Karlsson M; Gordin A
J Neurol Neurosurg Psychiatry; 2000 May; 68(5):589-94. PubMed ID: 10766888
[TBL] [Abstract][Full Text] [Related]
12. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.
Paija O; Laine K; Kultalahti ER; Leinonen M; Huupponen R; Gordin A; Reinikainen K
Clin Neuropharmacol; 2005; 28(3):115-9. PubMed ID: 15965309
[TBL] [Abstract][Full Text] [Related]
13. Levodopa-entacapone-carbidopa intestinal gel infusion in advanced Parkinson's disease: real-world experience and practical guidance.
Nyholm D; Jost WH
Ther Adv Neurol Disord; 2022; 15():17562864221108018. PubMed ID: 35785401
[TBL] [Abstract][Full Text] [Related]
14. Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study.
Senek M; Nielsen EI; Nyholm D
Mov Disord; 2017 Feb; 32(2):283-286. PubMed ID: 27987231
[TBL] [Abstract][Full Text] [Related]
15. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
Ferreira JJ; Almeida L; Cunha L; Ticmeanu M; Rosa MM; Januário C; Mitu CE; Coelho M; Correia-Guedes L; Morgadinho A; Nunes T; Wright LC; Falcão A; Sampaio C; Soares-da-Silva P
Clin Neuropharmacol; 2008; 31(1):2-18. PubMed ID: 18303486
[TBL] [Abstract][Full Text] [Related]
16. Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.
Heikkinen H; Varhe A; Laine T; Puttonen J; Kela M; Kaakkola S; Reinikainen K
Br J Clin Pharmacol; 2002 Oct; 54(4):363-71. PubMed ID: 12392583
[TBL] [Abstract][Full Text] [Related]
17. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.
Heikkinen H; Nutt JG; LeWitt PA; Koller WC; Gordin A
Clin Neuropharmacol; 2001; 24(3):150-7. PubMed ID: 11391126
[TBL] [Abstract][Full Text] [Related]
18. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
Rocha JF; Falcão A; Santos A; Pinto R; Lopes N; Nunes T; Wright LC; Vaz-da-Silva M; Soares-da-Silva P
Eur J Clin Pharmacol; 2014 Sep; 70(9):1059-71. PubMed ID: 24925090
[TBL] [Abstract][Full Text] [Related]
19. Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.
Müller T; Schlegel E; Zingler S; Thiede HM
Cells; 2022 Apr; 11(9):. PubMed ID: 35563817
[TBL] [Abstract][Full Text] [Related]
20. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers.
Ahtila S; Kaakkola S; Gordin A; Korpela K; Heinävaara S; Karlsson M; Wikberg T; Tuomainen P; Männistö PT
Clin Neuropharmacol; 1995 Feb; 18(1):46-57. PubMed ID: 8665534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
